08 December 2017

The Foundation's 2017 Donations

In 2017, the Foundation donated a total of $144,000 to four beneficiaries.

Black Dog Institute

The Foundation’s $19,250 donation will help to improve the lives of people living with mental illnesses such as depression, anxiety and bipolar disorder. It allows the Black Dog Institute to continue their ground-breaking research to develop better clinical treatments and prevention programs, as well as expand education programs to reach more communities, schools and health professionals.

Pink Angel

The Foundation’s $19,250 donation will allow Pink Angel to continue its mission of caring for, helping and supporting breast cancer patients in large regional areas.

Griffith University (Active Rehabilitation Physiotherapy)

The $55,000 donated by the Foundation will support one of the first human research projects in the use of Photobiomodulation Therapy (PBMt) to enhance the results of standard physiotherapy for patients with Parkinson’s.

Parkinson’s disease is not well understood and is the second most common neurological disease in Australia, with prevalence increasing by 17% in the last six years. Research conducted by a team of Australian Physiologists at the University of Sydney suggests protective, regenerative and potentially reversal effects of PBMt on nerve cells in a range of neurological conditions, including Parkinson’s.

Australian Liver Foundation

ALF was established in response to the huge and growing need for more research into diseases of the liver and bile duct, particularly liver cancer, which is the second largest cause of death in the world.

With the Foundation’s third donation to the ALF (taking the total to $150,000) Dr Richard Skoien continues his investigation into specific circulating markers in the blood to detect liver cancer at an early stage.

Outcomes for patients with primary liver cancer, also known as hepatocellular carcinoma (HCC), depend critically on early diagnosis. Unfortunately, the probability of someone surviving for 5 years after HCC is only 15%. In contrast, early diagnosis and treatment of small HCCs carries an excellent prognosis but early identification is limited by the lack of acute diagnostic tests.
This project aims to identify a “signature” of circulating genetic material called “microRNA” for HCC, and to use these microRNAs to develop a novel diagnostic test to identify early liver cancer.

A breakdown of the Foundation’s 2016 donations can be viewed here.

Donations to the Cromwell Foundation of more than $2 are tax deductible. To donate or seek more information, visit www.cromwellfoundation.org.au.